Recent studies have demonstrated that CARs modified with CXCR1/2 significantly enhance the migration and persistence of T cells in various cancers, including glioblastoma, ovarian cancer, pancreatic cancer, and hepatocellular carcinoma (Jin et al.2019; Liu et al.2020; Whilding et al.2019). The gene discussed is CXCR1; the disease is cancer.